You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


GlaxoSmithKline to close Sirtris unit in Cambridge

Company to absorb a few staffers

While other major pharmaceutical companies are scrambling for a spot in Kendall Square’s hotbed of biotechnology, GlaxoSmithKline is closing the Cambridge headquarters of its Sirtris Pharmaceuticals Inc. subsidiary.

Glaxo bought Sirtris for $720 million in 2008 to acquire research that captured the imagination of many as a potential high-tech fountain of youth. Now Sirtris’s research — and a handful of its employees — will be folded into Glaxo’s research and development operations in Philadelphia, spokeswoman Melinda Stubbee said Tuesday.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week